Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.

Haematologica - 1 Apr 2024

Cournoyer Eily, Ferrell Justin, Sharp Susan, Ray Anish, Jordan Michael, Dandoy Christopher, Grimley Michael, Roy Somak, Lorsbach Robert, Merrow Arnold C, Nelson Adam, Bartlett Allison, Picarsic Jennifer, Kumar Ashish

Abstract excerpt

The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although the failure rates are high. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEK-inhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and there are no data on the use of these inhibitors as first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Histiocytosis, Langerhans-Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imidazoles

Share to Mutation

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 37731389
DOI: 10.3324/haematol.2023.283295
PMCID: PMC10985423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.PMID 37731389Read ↗

Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.Semantic proximity Read ↗

Dabrafenib as a Therapeutic Option for Chemotherapy-Refractory pediatric Juvenile Xanthogranuloma: A Case ReportSemantic proximity Read ↗

Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.Semantic proximity Read ↗

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.Semantic proximity Read ↗

Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.Semantic proximity Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.